Sanofi will gain exclusivity rights to Ventyx Biosciences’ CNS-penetrant candidate VTX3232 as part of a $27m deal. Under the ...

EST Ventyx Biosciences (VTYX) files to sell 7.06M shares of common stock for holders Published first on TheFly – the ultimate ...

Sanofi will keep a significant stake in the ... in their technology within immunology and neurology. We've invested in Ventyx, focused in autoimmune and inflammatory disorders with an NLRP3 ...

Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after employment and investment guarantees relieved political controversy. The ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Sanofi Ventures – focused on early-to-mid stage investing, company co-creation, leading financing rounds, and prioritising those companies advancing innovation – has announced an additional ...

Sanofi is deepening its commitment to targeted radiation treatments for cancer with a €300 million equity investment in a new entity pursuing next-generation radioligand therapies. The new ...

Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...

PARIS, Oct 21 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U ...

PARIS, Oct 16 (Reuters) - French unions have called on workers at Sanofi (SASY.PA), opens new tab to strike from Thursday to protest a planned sale of the pharmaceutical group's consumer health ...

Sanofi SAN-1.01%decrease; red down pointing triangle moved ahead with a plan to sell a controlling stake in its consumer-healthcare unit Opella to Clayton Dubilier & Rice, entering exclusive talks ...